Ascendis Pharma

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ASND and other ETFs, options, and stocks.

About ASND

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet medical needs. 

CEO
Jan Møller Mikkelsen
CEOJan Møller Mikkelsen
Employees
Employees
Headquarters
Hellerup, Capital Region
HeadquartersHellerup, Capital Region
Founded
2006
Founded2006
Employees
Employees

ASND Key Statistics

Market cap
12.83B
Market cap12.83B
Price-Earnings ratio
-49.45
Price-Earnings ratio-49.45
Dividend yield
Dividend yield
Average volume
755.91K
Average volume755.91K
High today
$218.50
High today$218.50
Low today
$205.25
Low today$205.25
Open price
$210.52
Open price$210.52
Volume
678.59K
Volume678.59K
52 Week high
$223.19
52 Week high$223.19
52 Week low
$118.03
52 Week low$118.03

Stock Snapshot

Ascendis Pharma(ASND) stock is priced at $210.01, giving the company a market capitalization of 12.83B. It carries a P/E multiple of -49.45.

During the trading session on 2025-11-27, Ascendis Pharma(ASND) shares reached a daily high of $218.50 and a low of $205.25. At a current price of $210.01, the stock is +2.3% higher than the low and still -3.9% under the high.

Trading activity shows a volume of 678.59K, compared to an average daily volume of 755.91K.

Over the past 52 weeks, Ascendis Pharma(ASND) stock has traded between a high of $223.19 and a low of $118.03.

Over the past 52 weeks, Ascendis Pharma(ASND) stock has traded between a high of $223.19 and a low of $118.03.

ASND News

Simply Wall St 5h
Is There an Opportunity in Ascendis Pharma After Regulatory Approval Fuels 52% Rally in 2025?

Thinking about Ascendis Pharma and wondering if it could be a hidden value play? You are not alone. Investors are always searching for overlooked opportunities,...

Is There an Opportunity in Ascendis Pharma After Regulatory Approval Fuels 52% Rally in 2025?
TipRanks 1d
Ascendis Pharma Faces FDA Delay for TransCon CNP Approval

TipRanks Black Friday Sale Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to Tip...

TipRanks 2d
Ascendis Pharma annouces FDA extension for TransCon CN

Ascendis Pharma (ASND) announced that the FDA notified the Company that information submitted on November 5 related to the post-marketing requirement, in respon...

Analyst ratings

100%

of 15 ratings
Buy
100%
Hold
0%
Sell
0%
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.